AR084916A1 - Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas - Google Patents
Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicasInfo
- Publication number
- AR084916A1 AR084916A1 ARP120100213A ARP120100213A AR084916A1 AR 084916 A1 AR084916 A1 AR 084916A1 AR P120100213 A ARP120100213 A AR P120100213A AR P120100213 A ARP120100213 A AR P120100213A AR 084916 A1 AR084916 A1 AR 084916A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- ring
- haloalkyl
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- -1 C (O) NRfRg Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Compuestos de pirazol caracterizados porque tienen la fórmula (1) ó (2) y sales farmacéuticamente aceptables de los mismos, en los que: Ra y Rb se seleccionan independientemente de: hidrógeno, hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8 o Ra y Rb junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo o Ra y Rb junto con el átomo de carbono al que están unidos forman un anillo de 3 a 8 miembros, en los que dicho anillo puede contener 1 ó 2 heteroátomos seleccionados de O, N y S como miembro del anillo y en los que los miembros del anillo de dicho anillo pueden estar opcionalmente independientemente sustituidos por: hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8; Rc y Rd se seleccionan independientemente de: hidrógeno, hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8 o Rc y Rd junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo o Rc y Rd junto con el átomo de carbono al que están unidos forman un anillo de 3 a 8 miembros, en los que dicho anillo puede contener 1 ó 2 heteroátomos seleccionados de O, N y S como miembro del anillo y en los que los miembros del anillo de dicho anillo pueden estar opcionalmente independientemente sustituidos por: hidroxi, halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8; Y1, Y2, Y3, Y4 e Y5 se seleccionan independientemente de N y CRy, en los que cada Ry se selecciona independientemente de: H, hidroxi, halógeno, ciano, nitro, SF5, C(O)NRfRg, alquilo C1-6, hidroxi-alquilo C1-6, [alcoxi C1-6]alquilo C1-6, cicloalquilo C3-8, haloalquilo C1-6, alcoxi C1-6, [alcoxi C1-6]alcoxi C1-6, haloalcoxi C1-6, cicloalcoxi C3-8, alquilamino C1-6, di-alquilamino C1-6, alquilsulfonilo C1-6, fenilo, fenoxi, heterociclilo de 5 ó 6 miembros y heterocicliloxi de 5 ó 6 miembros, en los que Rf y Rg se seleccionan independientemente entre sí de: H, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo de 5 ó 6 miembros o Rf y Rg junto con el átomo de nitrógeno al que están unidos forman una amina cíclica, que puede comprender un heteroátomo más seleccionado de O, N y S como miembro del anillo; Z se selecciona de O, S y NRz, en el que Rz es H, alquilo C1-6 o bencilo; R1 y R2 independientemente entre sí se seleccionan de: H, halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquiltio C1-6, -NRfRg, cicloalquilo C3-8, [cicloalquil C3-8]-alquilo C1-6, [cicloalquil C3-8]-alquenilo C2-6, cicloalquenilo C3-8, [cicloalquenil C3-8]alquilo C1-6, [cicloalquenil C3-8]alquenilo C2-6, fenilo, fenil-alquilo C1-6, fenil-alquenilo C2-6, naftilo, naftil-alquilo C1-6, naftil-alquenilo C2-6, heterociclilo, heterociclil-alquilo C1-6 y heterociclil-alquenilo C2-6, en los que los restos alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 en los radicales mencionados R1 y R2 son no sustituidos o soportan al menos un sustituyente seleccionado de: hidroxi, halógeno, ciano, nitro, alcoxi C1-6, haloalcoxi C1-6, alquilamino C1-6, dialquilamino C1-6 y alquilsulfonilo C1-6 y/o en los que dos radicales unidos al mismo átomo de carbono de dichos restos alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 en los radicales mencionados R1 y R2 junto con dicho átomo de carbono pueden formar un grupo carbonilo y en los que los restos cicloalquilo C3-8, cicloalquenilo, fenilo, naftilo y heterociclilo en los radicales mencionados R1 y R2 son no sustituidos o soportan al menos un sustituyente seleccionado de: hidroxi, halógeno, ciano, nitro, alquilo C1-6, cicloalquilo C3-8, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, alquilamino C1-6, di-alquilamino C1-6, alquilsulfonilo C1-6, fenilo y hetarilo de 5 ó 6 miembros y/o en los que dos radicales unidos al mismo átomo de carbono de dichos restos cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo de los radicales R1 y R2 junto con dicho átomo de carbono pueden formar un grupo carbonilo y en los que Rf y Rg se seleccionan independientemente entre sí de: H, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8, cicloalquenilo C3-8 y heterociclilo o Rf y Rg junto con el átomo de nitrógeno al que están unidos forman una amina cíclica, que puede comprender un heteroátomo más seleccionado de O, N y S como miembro del anillo; n es un número entero seleccionado de 0, 1, 2 ó 3; y R3 si están presentes se seleccionan independientemente entre sí de: halógeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 y cicloalquilo C3-8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151876 | 2011-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084916A1 true AR084916A1 (es) | 2013-07-10 |
Family
ID=43799503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100213A AR084916A1 (es) | 2011-01-24 | 2012-01-23 | Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8759386B2 (es) |
| EP (1) | EP2668181B1 (es) |
| JP (1) | JP5695216B2 (es) |
| KR (2) | KR101923365B1 (es) |
| CN (4) | CN104961732B (es) |
| AP (1) | AP3343A (es) |
| AR (1) | AR084916A1 (es) |
| AU (1) | AU2012210718B2 (es) |
| BR (1) | BR112013017570B1 (es) |
| CA (1) | CA2825458C (es) |
| CL (1) | CL2013001945A1 (es) |
| CO (1) | CO6801731A2 (es) |
| CY (1) | CY1116012T1 (es) |
| DK (1) | DK2668181T3 (es) |
| EA (1) | EA022559B1 (es) |
| EC (1) | ECSP13012832A (es) |
| ES (1) | ES2529452T3 (es) |
| GE (1) | GEP20156332B (es) |
| HR (1) | HRP20150069T1 (es) |
| IL (1) | IL226920A (es) |
| MA (1) | MA34838B1 (es) |
| MX (1) | MX342830B (es) |
| MY (1) | MY163012A (es) |
| PE (1) | PE20140860A1 (es) |
| PH (2) | PH12013501356A1 (es) |
| PL (1) | PL2668181T3 (es) |
| PT (1) | PT2668181E (es) |
| RS (1) | RS53785B1 (es) |
| SG (1) | SG192096A1 (es) |
| SI (1) | SI2668181T1 (es) |
| TN (1) | TN2013000280A1 (es) |
| TW (1) | TWI527809B (es) |
| UA (1) | UA109696C2 (es) |
| UY (1) | UY33873A (es) |
| WO (1) | WO2012101043A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759386B2 (en) * | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| JP5999387B2 (ja) * | 2011-03-25 | 2016-09-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｒｔｈ２拮抗薬としてのピラゾール化合物 |
| US20140148492A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Bicyclosubstituted pyrazole compounds for treating hair loss |
| US20140148484A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| EA202092275A1 (ru) * | 2018-03-23 | 2021-02-09 | Палатин Текнолоджиз, Инк. | Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| WO2025009852A1 (ko) * | 2023-07-03 | 2025-01-09 | 주식회사 이노보테라퓨틱스 | 신규한 피라졸 유도체 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260322A (en) | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
| JP3723071B2 (ja) | 1999-11-10 | 2005-12-07 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| PT1471057E (pt) | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| DE602004011966T2 (de) | 2003-10-24 | 2009-02-12 | Glaxo Group Ltd., Greenford | Heterocyclylverbindungen |
| WO2006066879A2 (en) * | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| JP4950542B2 (ja) * | 2006-04-07 | 2012-06-13 | 岩手東芝エレクトロニクス株式会社 | 固体撮像装置およびその製造方法 |
| EP2040700B1 (en) | 2006-06-06 | 2010-11-24 | Glaxo Group Limited | N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
| UA92833C2 (en) * | 2006-11-27 | 2010-12-10 | Пфайзер Продактс Инк. | Pyrazole analogues |
| CN101874024A (zh) | 2007-09-25 | 2010-10-27 | 艾克提麦斯医药品有限公司 | 作为crth2拮抗剂的2-s-苄基取代的嘧啶 |
| CN101874023A (zh) | 2007-09-25 | 2010-10-27 | 艾克提麦斯医药品有限公司 | 作为crth2拮抗剂的烷硫基嘧啶 |
| JP2011088826A (ja) * | 2008-01-31 | 2011-05-06 | Astellas Pharma Inc | 芳香族カルボン酸化合物 |
| MX2010014172A (es) * | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| JP2012517405A (ja) * | 2009-02-09 | 2012-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器及び胃腸の疾患の治療のための新規医薬組成物 |
| CN108383789A (zh) * | 2010-01-27 | 2018-08-10 | 艾克提麦斯医药品有限公司 | 作为crth2拮抗剂的吡唑化合物 |
| WO2012013567A1 (en) * | 2010-07-28 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US8759386B2 (en) * | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
-
2012
- 2012-01-19 US US13/353,621 patent/US8759386B2/en active Active
- 2012-01-19 TW TW101102302A patent/TWI527809B/zh not_active IP Right Cessation
- 2012-01-20 MY MYPI2013002719A patent/MY163012A/en unknown
- 2012-01-20 ES ES12700695.5T patent/ES2529452T3/es active Active
- 2012-01-20 EP EP12700695.5A patent/EP2668181B1/en active Active
- 2012-01-20 CA CA2825458A patent/CA2825458C/en active Active
- 2012-01-20 PL PL12700695T patent/PL2668181T3/pl unknown
- 2012-01-20 CN CN201510362688.2A patent/CN104961732B/zh not_active Expired - Fee Related
- 2012-01-20 MA MA36130A patent/MA34838B1/fr unknown
- 2012-01-20 PH PH1/2013/501356A patent/PH12013501356A1/en unknown
- 2012-01-20 PE PE2013001586A patent/PE20140860A1/es active IP Right Grant
- 2012-01-20 CN CN201410837969.4A patent/CN104628705B/zh not_active Expired - Fee Related
- 2012-01-20 KR KR1020137019577A patent/KR101923365B1/ko not_active Expired - Fee Related
- 2012-01-20 CN CN201280006303.3A patent/CN103339125B/zh not_active Expired - Fee Related
- 2012-01-20 WO PCT/EP2012/050830 patent/WO2012101043A1/en not_active Ceased
- 2012-01-20 SI SI201230126T patent/SI2668181T1/sl unknown
- 2012-01-20 UA UAA201310232A patent/UA109696C2/uk unknown
- 2012-01-20 DK DK12700695.5T patent/DK2668181T3/da active
- 2012-01-20 MX MX2013008082A patent/MX342830B/es active IP Right Grant
- 2012-01-20 KR KR1020187033824A patent/KR102251939B1/ko not_active Expired - Fee Related
- 2012-01-20 HR HRP20150069AT patent/HRP20150069T1/hr unknown
- 2012-01-20 CN CN201710440429.6A patent/CN107011332B/zh not_active Expired - Fee Related
- 2012-01-20 GE GEAP201213204A patent/GEP20156332B/en unknown
- 2012-01-20 RS RS20150037A patent/RS53785B1/sr unknown
- 2012-01-20 AP AP2013006942A patent/AP3343A/xx active
- 2012-01-20 BR BR112013017570-2A patent/BR112013017570B1/pt not_active IP Right Cessation
- 2012-01-20 JP JP2013549819A patent/JP5695216B2/ja not_active Expired - Fee Related
- 2012-01-20 AU AU2012210718A patent/AU2012210718B2/en not_active Ceased
- 2012-01-20 PT PT127006955T patent/PT2668181E/pt unknown
- 2012-01-20 SG SG2013056106A patent/SG192096A1/en unknown
- 2012-01-20 EA EA201300857A patent/EA022559B1/ru not_active IP Right Cessation
- 2012-01-23 AR ARP120100213A patent/AR084916A1/es active IP Right Grant
- 2012-01-24 UY UY0001033873A patent/UY33873A/es unknown
-
2013
- 2013-06-13 IL IL226920A patent/IL226920A/en active IP Right Grant
- 2013-06-28 TN TNP2013000280A patent/TN2013000280A1/fr unknown
- 2013-06-28 CL CL2013001945A patent/CL2013001945A1/es unknown
- 2013-07-26 CO CO13177740A patent/CO6801731A2/es active IP Right Grant
- 2013-08-15 EC ECSP13012832 patent/ECSP13012832A/es unknown
-
2015
- 2015-02-02 CY CY20151100103T patent/CY1116012T1/el unknown
-
2018
- 2018-07-18 PH PH12018501531A patent/PH12018501531A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084916A1 (es) | Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas | |
| MX2015012815A (es) | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| MX2014000626A (es) | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa. | |
| AR082788A1 (es) | Composiciones pesticidas y procesos de preparacion de los mismos | |
| GT201200346A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| ECSP12012083A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR085149A1 (es) | Moduladores del receptor de glucagon | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| EA201891261A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |